Skip to main content
Erschienen in: BMC Infectious Diseases 1/2020

Open Access 01.12.2020 | Research article

Antimicrobial therapy and assessing therapeutic response in culture-negative pyogenic vertebral osteomyelitis: a retrospective comparative study with culture-positive pyogenic vertebral osteomyelitis

verfasst von: Dongwoo Yu, Sang Woo Kim, Ikchan Jeon

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2020

Abstract

Background

There are still controversies regarding the treatment and outcomes in culture-negative pyogenic vertebral osteomyelitis (PVO). The purpose of this study is to investigate the antimicrobial therapy, assessment of therapeutic response, and outcome of culture-negative PVO compared to culture-positive PVO.

Methods

A retrospective study was performed with non-surgical lumbar PVO patients. The patients were divided into two groups based on the causative bacterial identification (CN group with culture-negative PVO and CP group with culture-positive PVO). The clinical features, use of antibiotics, laboratory data, and outcomes were compared between the two groups.

Results

Seventy-three patients with 41 (56.2%) of the CN group and 32 (43.8%) of the CP group were enrolled. The CN group showed a shorter duration of parenteral antibiotics (45.88 ± 16.14 vs. 57.31 ± 24.39, p = 0.019) but a tendency of prolonged duration of total (parenteral + oral) antibiotics (101.17 ± 52.84 vs. 84.19 ± 50.29 days, p = 0.168). When parenteral antibiotics were discontinued or switched to oral antibiotics, the mean erythrocyte segmentation rate (ESR, normal range: < 25 mm/h), C-reactive protein (CRP, normal range: < 0.5 mg/dL) level, and visual analog scale (VAS) score of back pain were 42.86 ± 24.05 mm/h, 0.91 ± 1.18 mg/dL, and 4.05 ± 1.07, respectively, with no significant differences between the two groups. The recurrence rates of CN and CP groups were 7.3% (3/41) and 6.3% (2/32), respectively (p = 1.000). The presence of epidural abscess was the most significant factor for the identification of causative bacteria (p = 0.002), and there was no significant relationship between the use of empirical antibiotics before tissue culture and the causative bacterial identification (p = 0.194).

Conclusions

The CN group required a shorter duration of parenteral antibiotics than the CP group. Discontinuation of parenteral antibiotics or changing the administration route can be considered based on the values of ESR, CRP, and VAS score of back pain. The presence of epidural abscess was the most significant factor for the identification of causative bacteria.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PVO
Pyogenic vertebral osteomyelitis
ESR
Erythrocyte sedimentation rate
CRP
C-reactive protein
VAS
Visual analogue scale

Background

Vertebral osteomyelitis is an infectious disease that can develop by pyogenic, tuberculous, or brucellar causes [1]. The annual incidence of hospitalization with pyogenic vertebral osteomyelitis (PVO) in the United States between 1998 and 2013 rose from 2.9 to 5.4 per 100,000 individuals [2]. There is still no clear guidance regarding the duration and route of antibiotic administration. Generally, an extended course of parenteral antibiotics followed by a maintenance course of oral antibiotics is required in the treatment of PVO [35]. Infectious Diseases Society of America (IDSA) recommends 6 weeks of parenteral or highly bioavailable oral antimicrobial therapy for bacterial native vertebral osteomyelitis [6].
Identification of the causative bacteria and the use of appropriate antibiotics are necessary to achieve successful treatment and favorable outcomes in PVO. Despite a lot of effort, it is not always possible to identify the causative microorganism in clinical practice. About 50% of patients with PVO are treated with empirical antibiotics because PVO often shows negative in the microbiological culture test [7, 8]. The guidelines for the choice and preferred route of antibiotic administration for culture-negative PVO have not been well established owing to insufficient relevant research result, which is originated in the variety of causative microorganisms and rate of antibiotic resistance depending on the regions. Herein, we conducted a retrospective study to compare culture-negative PVO and culture-positive PVO in terms of clinical characteristics, use of antibiotics, assessment of therapeutic response, and outcomes.

Methods

Patients and data collection

This retrospective study was performed at a single tertiary-care university hospital from October 2014 to September 2018 and included 118 patients diagnosed as pyogenic lumbar PVO. Patients were excluded if they had tuberculous spondylitis, tumors, postoperative development, accompanying bone infection at another site, trauma, pregnancy, concomitant severe medical problems, less than six months of follow-up period, or age < 19 years. All clinical and radiological data were obtained and reviewed retrospectively from electronic charts under the approval of the institutional review board (Yeungnam University Hospital, 2020-06-091).

Diagnosis of PVO

PVO was diagnosed based on clinical symptoms, laboratory data, and radiological findings. The clinical symptoms included fever and back pain with or without radiating pain. Elevated erythrocyte segmentation rate (ESR, normal range: < 25 mm/h) or C-reactive protein (CRP, normal range: < 0.5 mg/dL) level or both along with specific magnetic resonance (MR) findings of PVO as a contiguous single lesion was an important clue for the diagnosis of PVO. In the extent of PVO lesion, a PVO lesion comprises the upper and lower vertebrae centering on the infected disc with or without epidural, psoas, and paraspinal abscesses; it was defined as one level (e.g., if there were two infected discs, then three vertebrae were included centering on the two infected discs, this PVO lesion was considered two levels) [9] .

Causative bacterial identification

Patients diagnosed as PVO were divided into two groups according to the results of causative bacterial identification. The microbiological diagnosis was confirmed through more than two sets of blood culture or tissue culture for the PVO lesion by computed tomography (CT)-guided needle biopsy or open surgical biopsy [10]. Patients with clinical symptoms and radiological findings indicative of PVO but without a confirmed causative bacterial identification were defined as the culture-negative group (CN group), and other patients in whom the causative microorganism was identified were defined as the culture-positive group (CP group).

Cure and recurrence

The patients underwent clinical assessment for therapeutic response after at least three weeks of parenteral antibiotic therapy, which was performed based on clinical symptoms (fever and back pain) and hematological inflammatory indices (CRP and ESR). The condition of being ‘Cured’ was defined as the absence of fever and resolution in back pain and improvement of CRP level, which continued during a follow-up period of at least six months without any other evidence of residual or recurrence of PVO. When a patient was determined as ‘Cured’ on clinical assessment for therapeutic response, antibiotic therapy was discontinued. The condition of being ‘Non-cured’ was defined as follows: persistence or re-aggravation of clinical symptoms and hematological indicies with the presence of fever and/or re-identification of same causative bacteria from blood/PVO lesion and the development of new or re-aggravation of the PVO lesion on MR imaging after discontinuation of antibiotic therapy within the follow-up period of at least six months [11, 12].

Functional and laboratory evaluations

All patients underwent the evaluation of clinical status and laboratory tests for the initial three months after the diagnosis of PVO and on starting antibiotic therapy. Visual analog scale (VAS) scores for back pain and laboratory data, including ESR and CRP at initial (at the time of diagnosis), 1 week, 1 month, and 3 months were compared between the two groups. VAS was used to estimate back pain, with 0 representing no pain to 10 representing maximum pain. The values of ESR and CRP when parenteral antibiotics were discontinued or switched to oral antibiotics were measured and compared between the two groups.

Statistical analysis

The Student’s t-test and the Mann-Whitney U test were used to compare parametric and non-parametric continuous variables, respectively. One-way analysis of variance (ANOVA) for parametric continuous variables and the Kruskal-Wallis test for non-parametric continuous variables were used to compare three population means. For categorical variables, the chi-square test was performed. Logistic regression analysis was used to investigate the clinical variables related to the identification of causative microorganisms. All clinical variables identified as statistically significant in univariate analyses were included in a multivariate analysis. Statistical analysis was carried out using SPSS version 25.0 software (SPSS Inc., Chicago, Illinois), and p values of < 0.05 were considered statistically significant.

Results

Demographic and clinical data

Among the 118 patients, 45 were excluded due to surgery-related development (n = 25), tuberculosis (n = 12), ankylosing spondylitis (n = 2), and follow-up loss (n = 6). The final analyses were performed on 73 patients (44 men and 29 women) with a mean age of 64.73 ± 11.61 (42-84) years. There were no statistically significant differences in age, gender, underlying diseases, and history of spinal procedures between the two groups. However, there were statistically significant differences in the extent of affected PVO lesion [1.49 ± 0.93 (1-5) vs. 2.09 ± 1.28 (1-5) levels, p = 0.022] and the presence of epidural abscess (43.9% [18/41] vs. 84.4% [27/32], p = 0.001), except the presence of psoas muscle and paraspinal abscess. The recurrence rates were 7.3% (3/41) and 6.3% (2/32), respectively (p = 1.000). Detailed data are mentioned in Table 1.
Table 1
Demographic and clinical data
 
CN group (n = 41)
CP group (n = 32)
p value a
Total (n = 73)
Age [year]
65.41 ± 11.60
61.83 ± 13.76
0.570
64.73 ± 11.61 (42-84)
Male sex
27 (65.9%)
17 (53.1%)
0.337
44 (60.3%)
BMI
22.97 ± 3.25
24.27 ± 3.75
0.120
23.54 ± 3.52
Underlying disease
 Diabetes mellitus
14 (34.1%)
7 (21.9%)
0.304
21 (28.8%)
 Rheumatic disease
3 (7.3%)
1 (3.1%)
0.626
4 (5.5%)
 Liver cirrhosis
2 (4.9%)
0 (0%)
0.501
2 (2.7%)
 Chronic kidney disease
1 (2.4%)
0 (0%)
1.000
1 (1.4%)
Alcohol
13 (31.7%)
4 (12.5%)
0.092
17 (23.3%)
Smoking
15 (36.6%)
6 (18.8%)
0.121
21 (28.8%)
History of spinal procedures
27 (65.9%)
18 (56.3%)
0.471
45 (61.6%)
 Epidural injection
25 (55.6%)
18 (50.0%)
0.659
43 (53.1%)
 Acupuncture [oriental medicine]
10 (24.4%)
4 (12.5%)
0.242
14 (19.2%)
Fever [°C, >  37.3]
11 (26.8%)
8 (25.0%)
1.000
19 (26.0%)
Neurological symptom
17 (41.5%)
20 (62.5%)
0.100
37 (50.7%)
Features of PVO
 Extent of affected lesion [level]
1.49 ± 0.93 (1-5)
2.09 ± 1.28 (1-5)
0.022
1.75 ± 1.13 (1-5)
 Epidural abscess
18 (43.9%)
27 (84.4%)
0.001
45 (61.6%)
 Psoas abscess
17 (41.5%)
13 (40.6%)
1.000
30 (41.1%)
 Paraspinal abscess
27 (65.6%)
23 (71.9%)
0.612
50 (68.5%)
Duration of hospital stay [days]
50.32 ± 19.96 (21-120)
62.88 ± 26.04 (26-143)
0.022
55.82 ± 23.51 (21-143)
Follow up period [months]
18.00 ± 11.16 (6-42)
16.38 ± 12.48 (6-63)
0.560
17.29 ± 11.70 (6-63)
Recurrence
3 (7.3%)
2 (6.3%)
1.000
5 (6.8%)
Data are presented as the mean ± standard deviation or frequency, CN culture negative, CP culture positive, BMI body mass index, PVO pyogenic vertebral osteomyelitis, a p value between group CN and CP, p values of < 0.05 were considered statistically significant.

Microorganisms and antibiotics

The rate of causative bacterial identification was only 43.8% (32/73) with 8 (25%) from blood culture, 15 (46.9%) from tissue culture of CT-guided needle or open surgical biopsy of the PVO lesion, and 9 (28.1%) from both blood and tissue cultures. According to the culture methods, 17 of 73 patients (23.3%) with blood cultures, 7 of 37 patients (18.9%) with CT-guided needle biopsy, and 17 of 36 patients (47.2%) with open surgical biopsy were identified. Microbiologic findings of the 32 patients in the CP group are shown in Table 2. The most common causative microorganism was Staphylococcus aureus (40.6%, 13/32). Five cases of recurrence were noted: one with methicillin-resistant Staphylococcus epidermidis, one with Enterobacter, and three with culture-negative cases. Detailed data are mentioned in Table 2.
Table 2
Microbiologic findings
Factors 
Values
Causative bacterial identification
32/73 (43.8%)
 Blood culture
8 (25.0%)
 Tissue culture of CT-guided needle biopsy on PVO lesion
5 (15.6%)
 Tissue culture of open biopsy on PVO lesion
10 (31.3%)
 Both (blood and tissue cultures)
9 (28.1%)
Positive culture rates depending on the methods
 Blood culture
17/73 (23.3%)
 Tissue culture of CT-guided needle biopsy on PVO lesion
7/37 (18.9%)
 Tissue culture of open biopsy on PVO lesion
17/36 (47.2%)
Microbiological findings (n = 32)
 Gram-positive bacteria
26 (81.3%)
  Staphylococcus aureus
13 (40.6%)
   MSSA
10 (31.2%)
   MRSA
3 (9.4%)
  Coagulase-negative staphylococci
4 (12.5%)
  Streptococcus species
6 (18.8%)
  Streptococcus agalactiae
2 (6.3%)
   Othersa
4 (12.5%)
  Enterococcus species
3 (9.4%)
 Gram-negative bacteria
6 (18.8%)
  Escherichia coli
2 (6.3%)
  Klebsiella pneumoniae
1 (3.1%)
  Acinetobactor baumannii
2 (6.3%)
  Enterobacter species
1 (3.1%)
Data are presented as frequency, PVO pyogenic vertebral osteomyelitis, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, a Streptococcus viridians, Streptococcus pneumoniae, and Streptococcus bovis
The antibiotic regimens for the treatment of PVO are summarized in Table 3. β-Lactam and glycopeptide were the mainly used as the effective antibiotics in both groups. The use of glycopeptide did not significantly differ between the two groups. However, quinolones were used statistically significantly more in the CN group (22.0% [9/41] vs. 3.1% [1/41], p = 0.036). Antibiotics were administered before tissue culture of the PVO lesion in 71.2% cases (52/73), and there was no significant difference between the two groups (78.0% [32/41] vs. 62.5% [20/32], p = 0.194). There was no statistically significant difference in the duration of total antibiotics between the two groups (101.17 ± 52.84 of CN group vs. 84.19 ± 50.29 days of CP group, p = 0.168). However, there were statistically significant differences in the duration of parenteral antibiotics (45.88 ± 16.14 vs. 57.31 ± 24.39, p = 0.019), oral antibiotics (55.29 ± 47.40 vs. 26.84 ± 41.10, p = 0.009), and the incidence of using oral antibiotics (75.6% [31/41] vs. 43.8% [14/32], p = 0.001) between the two groups, respectively. Detailed data are provided in Table 4.
Table 3
Regimens of antibiotics
 
CN group (n = 41)
CP group (n = 32)
p value #
Total (n = 73)
Parenteral antibiotics
41 (100%)
32 (100%)
73 (100%)
 β-Lactam
15 (36.6%)
11 (34.4%)
1.000
26 (35.6%)
  1st generation cephalosporin
10 (24.4%)
3 (9.4%)
0.128
13 (17.8%)
  3rd generation cephalosporin
4 (9.8%)
2 (6.3%)
0.689
6 (8.2%)
  Nafcillin
1 (2.4%)
6 (18.8%)
0.039
7 (9.6%)
 β-Lactam ± others a
6 (14.6%)
5 (15.6%)
1.000
11 (15.1%)
 Glycopeptide ± others b
11 (26.8%)
12 (37.5%)
0.447
23 (31.5%)
 Quinolone
9 (22.0%)
1 (3.1%)
0.036
10 (13.7%)
 Others c
0 (0%)
3 (9.4%)
0.080
3 (4.1%)
Oral antibiotics
33 (77.8%)
12 (38.9%)
0.001
49 (60.5%)
 β-Lactam
7 (17.1%)
1 (3.1%)
0.072
8 (11.0%)
 Quinolone
26 (63.4%)
11 (34.4%)
0.019
37 (50.7%)
CN culture negative, CP culture positive, Data are presented as frequency, a β-lactamase inhibitor, aminoglycoside, b Gentamicin and tazime, c Carbapenem, prepenem, and linezoid, # p value between the CN and CP groups, p values of < 0.05 were considered statistically significant
Table 4
Comparison of antibiotic treatment between the CN and CP groups
 
CN group (n = 41)
CP group (n = 32)
p value #
Total (n = 73)
Use of antibiotics before tissue-culture
32/41(78.0%)
20/32 (62.5%)
0.194
52/73 (71.2%)
Duration of antibiotic treatment (days)
 Total [parenteral + oral]
101.17 ± 52.84 (31-209)
84.19 ± 50.29 (25-198)
0.168
93.73 ± 52.08 (25-209)
 Parenteral
45.88 ± 16.14 (17-95)
57.31 ± 24.39 (25-144)
0.019
50.89 ± 20.82 (17-144)
 Oral
55.29 ± 47.40 (0-166)
26.84 ± 41.10 (0-126)
0.009
42.82 ± 46.66 (0-166)
Incidence of using oral antibiotics
31/41(75.6%)
14/32, (43.8%)
0.001
45/73 (61.6%)
Data are presented as the mean ± standard deviation or frequency, CN culture negative, CP culture positive, # p value between group CN and CP, p values of < 0.05 were considered statistically significant
The clinical variables related to the causative bacterial identification are presented in Table 5. The clinical variables with statistical significance identified in a univariate logistic regression analysis were included in a multivariate logistic regression analysis. Epidural abscess and initial VAS score of back pain were statistically significant predictors.
Table 5
Logistic regression analysis in the correlation between the causative bacterial identification (culture positive) and variable clinical variables
Clinical variable
Univariate
Multivariate
OR
95% CI
p value
OR
95% CI
p value
Open surgical biopsy
3.31
1.26-8.71
0.015
   
Extent of affected lesion
1.65
1.06-2.58
0.027
   
Epidural abscess
6.90
2.22-21.49
0.001
6.57
2.00-21.57
0.002*
Initial CRP
1.08
1.02-1.14
0.009
   
Initial back VAS
2.00
1.21-3.33
0.007
1.95
1.13-3.38
0.017*
OR odds ratio, CI confidential interval, CRP C-reactive protein (normal range < 0.5 mg/dL), VAS visual analog scale, p values of < 0.05 were considered statistically significant

Changes of ESR/CRP and VAS score for back pain during the early 3-month after starting antibiotics

There were statistically significant improvements in ESR, CRP, and VAS score of back pain in both groups during early 3 months, respectively (p < 0.01). In ESR, there were no statistically significant differences at initial, 1 week, 1 month, and 3 months findings between the two groups. However, there were statistically significant differences in CRP (9.21 ± 7.43 vs. 15.17 ± 10.32 mg/dL, p = 0.005) and VAS score of back pain (7.41 ± 0.92 vs. 8.13 ± 1.13, p = 0.004) at initial assessment between the two groups, respectively. However, there were no statistically significant differences in CRP and ESR at 1-week, 1-month, and 3-month between the two groups, respectively. When parenteral antibiotics discontinued or changed to oral antibiotics, there were no statistically significant differences in ESR, CRP, and VAS score of back pain between the two groups. The values of ESR, CRP, and VAS score of back pain in total patients were 44.85 ± 24.99 mm/h, 0.89 ± 1.02 mg/dL, and 3.98 ± 1.08, respectively. Detailed data are provided in Table 6.
Table 6
Changes of ESR/CRP and VAS score of back pain during 3 months since antimicrobial therapy started
 
CN group (n = 41)
CP group (n = 32)
p value #
Total (n = 73)
ESR
 Initial (at diagnosis)
66.88 ± 31.89
72.44 ± 31.89
0.462
69.32 ± 31.79
 1 week
70.98 ± 33.81
74.31 ± 26.84
0.649
72.44 ± 30.79
 1 month
55.29 ± 29.94
61.31 ± 31.07
0.405
57.93 ± 30.37
 3 months
30.51 ± 19.65+
42.81 ± 31.44+
0.058
35.90 ± 26.03
CRP
 Initial (at diagnosis)*
9.21 ± 7.43
15.17 ± 10.32
0.005
11.83 ± 9.24
 1 week
5.67 ± 5.75
6.97 ± 5.74
0.339
6.24 ± 5.74
 1 month
1.89 ± 2.05
2.26 ± 2.75
0.516
2.06 ± 2.37
 3 months
0.58 ± 0.99+
0.79 ± 1.29+
0.427
0.67 ± 1.13
VAS score of back pain
 Initial (at diagnosis)*
7.41 ± 0.92
8.13 ± 1.13
0.004
7.73 ± 1.07
 1 week
5.73 ± 1.18
5.63 ± 1.39
0.724
5.68 ± 1.27
 1 month
4.32 ± 1.13
4.47 ± 1.27
0.591
4.38 ± 1.19
 3 months
3.37 ± 0.92+
3.44 ± 1.27+
0.780
3.39 ± 1.08
When discontinuation of parenteral antibiotics
 ESR
44.85 ± 24.99
40.31 ± 22.91
0.427
42.86 ± 24.05
 CRP
0.89 ± 1.02
0.93 ± 1.37
0.907
0.91 ± 1.18
 VAS score of back pain
3.98 ± 1.08
4.16 ± 1.05
0.476
4.05 ± 1.07
CN culture negative, CP culture positive, ESR erythrocyte segmentation rate (normal range < 25 mm/h), CRP C-reactive protein (normal range < 0.5 mg/dL), VAS visual analogue scale, # p value between group CN and CP, * There is statistical significant difference between the two groups (p < 0.01) +, There is statistical significant difference compared to initial value (p < 0.01), p values of < 0.05 were considered statistically significant

Discussion

The rate of causative bacterial identification varies as reported in the previous literatures [7, 11, 13], and this study showed lower rate with less than 50% compared to other reports. The result is expected to be the most relevant to the use of empirical antibiotics before tissue culture for the PVO lesion (52/73, 71.2%) due to poor general conditions, including high fever or sepsis, although blood cultures were performed in all patients before administering empirical antibiotics. However, there was no statistically significant relationship between the use of empirical antibiotics before tissue culture and the causative bacterial identification (32/41 in CN group vs. 20/32 in CP group, p = 0.194). There are still debates on the influence of empirical antibiotics before tissue culture on the microbiological diagnostic yield [1417]. In addition, the rate of causative bacterial identification in PVO varies with the method of culture. Generally, the rate of positive-culture is higher with an open surgical biopsy than with needle biopsy, which is related to the obtaining sufficient specimen quantity from the accurate area of the infectious lesion. In multivariate logistic regression analysis, the presence of epidural abscess was the most powerful statistically significant predictor of causative bacterial identification. PVOs with epidural abscess were more likely to present neurological deficits such as leg pain or weakness. These may require a surgical treatment for removing epidural abscess to relieve neurological symptoms, which also allows obtaining a sufficient quantity of proper specimen, thus leading to increased microbiological diagnostic yield despite the use of empirical antibiotics in advance.
In laboratory data, the initial CRP level was significantly lower in the CN group than in the CP group. Previous studies reported fewer infectious signs and lower values of inflammatory markers in patients with culture-negative PVO, which may have been due to small inocula of pathogens [11, 13, 18]. Kim et al. [18] showed that culture-positive PVO is more likely to be associated with body temperature ≥ 37.8 °C, higher initial ESR and CRP, and the presence of paraspinal abscess. In this study, similar results were presented with a larger extent of the affected lesion, presence of epidural abscess, worse back pain, and higher initial CRP level in the CP group. Among the regimens of antibiotics, more frequent use of quinolone as an effective antibiotic in the CN group also supports these results. We performed serial follow-up of ESR, CRP, and VAS score of back pain. By the 3rd month, the CRP level had almost normalized and VAS scores had decreased by more than 50% of the initial scores. However, despite a tendency of continuous decline, the value of ESR remained consistently higher than normal. There were no statistically significant differences in ESR, CRP, and VAS score of back pain at 3 months between the two groups. We assume that the mechanical stress on the injured intervertebral disc and endplates as well as the restoration process of the PVO lesion, which may result in the persistent elevated ESR and VAS score of back pain. The values of ESR, CRP, and VAS score of back pain at the time of discontinuation of parenteral antibiotics or switching to oral antibiotics were 42.86 ± 24.05 mm/h, 0.91 ± 1.18 mg/dL, and 4.05 ± 1.07, respectively. There were no statistically significant differences between the two groups. We think that the values of ESR, CRP, and VAS score of back pain are meaningful and can help assess therapeutic response and decide regarding discontinuation of parenteral antibiotics or changing to oral antibiotics.
The recurrence rates reported in previous literatures have varied greatly. McHenry et al. [19] reported a recurrence rate of 14% in 253 patients, Park et al. [10] of 9.9% in 314 patients, and Kim et al. [18] of 6.6% in 151 patients. Unfortunately, data to guide the optimal duration of antibiotic therapy related to the recurrence of PVO are insufficient [7, 2023]. Some studies reported that less than 6-8 weeks of antibiotic therapy may be associated with an increased risk of recurrence [18, 19, 24, 25]. Compared to the results of many previous literatures, our results showed relatively longer duration of antibiotics and lower recurrence rate of 6.8%. Kim et al. [18] reported a similar recurrence rate of 6.6% with an average of more than 100 days of the total antibiotics. Based on these results, we expect prolonged antibiotic therapy to be helpful in preventing recurrence. As mentioned above, culture-negative PVO shows fewer infectious signs and lower values of inflammatory markers, which may also be associated with a shorter duration of parenteral antibiotic therapy than in culture-positive PVO. However, as higher CRP level is usually associated with a higher risk of treatment failure in PVO, switching from parenteral antibiotics to oral antibiotics may be favorable in cases with lower CRP level [18, 26]. We think that the assessment of therapeutic response based on laboratory data allows for shortening the duration of parenteral antibiotics and hospital stay with favorable outcomes, particularly, under an environment with low rates of causative bacterial identification. However, we could not clearly explain the reasons for the frequent use and longer duration of oral antibiotics in culture-negative PVO. Considering the similar recurrence rate between the two groups, oral antibiotics are expected to prevent the recurrence despite the relatively short period of parenteral antibiotics in culture-negative PVO.
There were several limitations in this study. First, it was a retrospective study with relatively small number of participants, which may have resulted in an underpowered statistical analysis. Second, the sample size of patients who experienced recurrence was small, and thus the statistical analysis of several factors related to recurrence was impossible. Third, false-positives in the assessment of the therapeutic response requiring additional antibiotic therapy could not be accurately identified, which could have led to the unnecessary use of antibiotics. To overcome these limitations, further studies with a larger number of participants under a prospective design are required.

Conclusion

Culture-negative PVO required a shorter duration of parenteral antibiotics and enabled changing to oral antibiotics compared to culture-positive PVO in terms of achieving similar outcomes. Discontinuation of parenteral antibiotics or switching to oral antibiotics can be considered based on the values of ESR, CRP, and VAS score for back pain. The presence of epidural abscess was the most significant factor for the identification of causative bacteria in PVO, which is associated with obtaining sufficient proper specimen via surgical culture.

Acknowledgements

Not applicable.
All participants in this study were anonymized. The use of data from the hospital database for the analysis was approved by the institutional review board (Yeungnam University Hospital, 2020-06-091). Written informed consent was waived due to retrospective study design.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Colmenero JD, Jimenez-Mejias ME, Sanchez-Lora FJ, Reguera JM, Palomino-Nicas J, Martos F, Garcia de las Heras J, Pachon J. Pyogenic, tuberculous, and brucellar vertebral osteomyelitis: a descriptive and comparative study of 219 cases. Ann Rheum Dis. 1997;56(12):709–15.CrossRef Colmenero JD, Jimenez-Mejias ME, Sanchez-Lora FJ, Reguera JM, Palomino-Nicas J, Martos F, Garcia de las Heras J, Pachon J. Pyogenic, tuberculous, and brucellar vertebral osteomyelitis: a descriptive and comparative study of 219 cases. Ann Rheum Dis. 1997;56(12):709–15.CrossRef
2.
Zurück zum Zitat Issa K, Diebo BG, Faloon M, Naziri Q, Pourtaheri S, Paulino CB, Emami A. The epidemiology of vertebral osteomyelitis in the United States from 1998 to 2013. Clin Spine Surg. 2018;31(2):E102–8.CrossRef Issa K, Diebo BG, Faloon M, Naziri Q, Pourtaheri S, Paulino CB, Emami A. The epidemiology of vertebral osteomyelitis in the United States from 1998 to 2013. Clin Spine Surg. 2018;31(2):E102–8.CrossRef
3.
Zurück zum Zitat Butler JS, Shelly MJ, Timlin M, Powderly WG, O'Byrne JM. Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. Spine (Phila Pa 1976). 2006;31(23):2695–700.CrossRef Butler JS, Shelly MJ, Timlin M, Powderly WG, O'Byrne JM. Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. Spine (Phila Pa 1976). 2006;31(23):2695–700.CrossRef
4.
Zurück zum Zitat Friedman JA, Maher CO, Quast LM, McClelland RL, Ebersold MJ. Spontaneous disc space infections in adults. Surg Neurol. 2002;57(2):81–6.CrossRef Friedman JA, Maher CO, Quast LM, McClelland RL, Ebersold MJ. Spontaneous disc space infections in adults. Surg Neurol. 2002;57(2):81–6.CrossRef
5.
Zurück zum Zitat Sobottke R, Seifert H, Fatkenheuer G, Schmidt M, Gossmann A, Eysel P. Current diagnosis and treatment of spondylodiscitis. Dtsch Arztebl Int. 2008;105(10):181–7.PubMedPubMedCentral Sobottke R, Seifert H, Fatkenheuer G, Schmidt M, Gossmann A, Eysel P. Current diagnosis and treatment of spondylodiscitis. Dtsch Arztebl Int. 2008;105(10):181–7.PubMedPubMedCentral
6.
Zurück zum Zitat Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM 3rd, Petermann GW, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26–46.CrossRef Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM 3rd, Petermann GW, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26–46.CrossRef
7.
Zurück zum Zitat Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010;362(11):1022–9.CrossRef Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010;362(11):1022–9.CrossRef
8.
Zurück zum Zitat Park KH, Cho OH, Jung M, Suk KS, Lee JH, Park JS, Ryu KN, Kim SH, Lee SO, Choi SH, et al. Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria. J Inf Secur. 2014;69(1):42–50. Park KH, Cho OH, Jung M, Suk KS, Lee JH, Park JS, Ryu KN, Kim SH, Lee SO, Choi SH, et al. Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria. J Inf Secur. 2014;69(1):42–50.
9.
Zurück zum Zitat Jeon I, Kong E, Yu D, Hong CP. Clinical and radiological analysis of pyogenic vertebral osteomyelitis immediately after successful antimicrobial therapy: considerations for assessing therapeutic response. Diagnostics. 2020;10(11). Jeon I, Kong E, Yu D, Hong CP. Clinical and radiological analysis of pyogenic vertebral osteomyelitis immediately after successful antimicrobial therapy: considerations for assessing therapeutic response. Diagnostics. 2020;10(11).
10.
Zurück zum Zitat Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YP, Kim SH, Lee SO, et al. Optimal duration of antibiotic therapy in patients with Hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis. 2016;62(10):1262–9.CrossRef Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, Lee YM, Chong YP, Kim SH, Lee SO, et al. Optimal duration of antibiotic therapy in patients with Hematogenous vertebral osteomyelitis at low risk and high risk of recurrence. Clin Infect Dis. 2016;62(10):1262–9.CrossRef
11.
Zurück zum Zitat Lora-Tamayo J, Euba G, Narvaez JA, Murillo O, Verdaguer R, Sobrino B, Narvaez J, Nolla JM, Ariza J. Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum. 2011;41(2):247–55.CrossRef Lora-Tamayo J, Euba G, Narvaez JA, Murillo O, Verdaguer R, Sobrino B, Narvaez J, Nolla JM, Ariza J. Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum. 2011;41(2):247–55.CrossRef
12.
Zurück zum Zitat Russo A, Graziano E, Carnelutti A, Sponza M, Cadeo B, Sartor A, Righi E, Bassetti M. Management of vertebral osteomyelitis over an eight-year period: the UDIPROVE (UDIne PROtocol on VErtebral osteomyelitis). Int J Infect Dis. 2019;89:116–21.CrossRef Russo A, Graziano E, Carnelutti A, Sponza M, Cadeo B, Sartor A, Righi E, Bassetti M. Management of vertebral osteomyelitis over an eight-year period: the UDIPROVE (UDIne PROtocol on VErtebral osteomyelitis). Int J Infect Dis. 2019;89:116–21.CrossRef
13.
Zurück zum Zitat Bhagat S, Mathieson C, Jandhyala R, Johnston R. Spondylodiscitis (disc space infection) associated with negative microbiological tests: comparison of outcome of suspected disc space infections to documented non-tuberculous pyogenic discitis. Br J Neurosurg. 2007;21(5):473–7.CrossRef Bhagat S, Mathieson C, Jandhyala R, Johnston R. Spondylodiscitis (disc space infection) associated with negative microbiological tests: comparison of outcome of suspected disc space infections to documented non-tuberculous pyogenic discitis. Br J Neurosurg. 2007;21(5):473–7.CrossRef
14.
Zurück zum Zitat de Lucas EM, Gonzalez Mandly A, Gutierrez A, Pellon R, Martin-Cuesta L, Izquierdo J, Sanchez E, Ruiz E, Quintana F. CT-guided fine-needle aspiration in vertebral osteomyelitis: true usefulness of a common practice. Clin Rheumatol. 2009;28(3):315–20.CrossRef de Lucas EM, Gonzalez Mandly A, Gutierrez A, Pellon R, Martin-Cuesta L, Izquierdo J, Sanchez E, Ruiz E, Quintana F. CT-guided fine-needle aspiration in vertebral osteomyelitis: true usefulness of a common practice. Clin Rheumatol. 2009;28(3):315–20.CrossRef
15.
Zurück zum Zitat Hassoun A, Taur Y, Singer C. Evaluation of thin needle aspiration biopsy in the diagnosis and management of vertebral osteomyelitis (VO). Int J Infect Dis. 2006;10(6):486–7.CrossRef Hassoun A, Taur Y, Singer C. Evaluation of thin needle aspiration biopsy in the diagnosis and management of vertebral osteomyelitis (VO). Int J Infect Dis. 2006;10(6):486–7.CrossRef
16.
Zurück zum Zitat Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK. The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis. 2011;52(7):867–72.CrossRef Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK. The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis. 2011;52(7):867–72.CrossRef
17.
Zurück zum Zitat Rankine JJ, Barron DA, Robinson P, Millner PA, Dickson RA. Therapeutic impact of percutaneous spinal biopsy in spinal infection. Postgrad Med J. 2004;80(948):607–9.CrossRef Rankine JJ, Barron DA, Robinson P, Millner PA, Dickson RA. Therapeutic impact of percutaneous spinal biopsy in spinal infection. Postgrad Med J. 2004;80(948):607–9.CrossRef
18.
Zurück zum Zitat Kim J, Kim YS, Peck KR, Kim ES, Cho SY, Ha YE, Kang CI, Chung DR, Song JH. Outcome of culture-negative pyogenic vertebral osteomyelitis: comparison with microbiologically confirmed pyogenic vertebral osteomyelitis. Semin Arthritis Rheum. 2014;44(2):246–52.CrossRef Kim J, Kim YS, Peck KR, Kim ES, Cho SY, Ha YE, Kang CI, Chung DR, Song JH. Outcome of culture-negative pyogenic vertebral osteomyelitis: comparison with microbiologically confirmed pyogenic vertebral osteomyelitis. Semin Arthritis Rheum. 2014;44(2):246–52.CrossRef
19.
Zurück zum Zitat McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis. 2002;34(10):1342–50.CrossRef McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. Clin Infect Dis. 2002;34(10):1342–50.CrossRef
20.
Zurück zum Zitat Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65(Suppl 3):iii11–24.PubMed Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65(Suppl 3):iii11–24.PubMed
21.
Zurück zum Zitat Zarghooni K, Rollinghoff M, Sobottke R, Eysel P. Treatment of spondylodiscitis. Int Orthop. 2012;36(2):405–11.CrossRef Zarghooni K, Rollinghoff M, Sobottke R, Eysel P. Treatment of spondylodiscitis. Int Orthop. 2012;36(2):405–11.CrossRef
22.
Zurück zum Zitat Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385(9971):875–82.CrossRef Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385(9971):875–82.CrossRef
23.
Zurück zum Zitat Lora-Tamayo J, Murillo O. Shorter treatments for vertebral osteomyelitis. Lancet. 2015;385(9971):836–7.CrossRef Lora-Tamayo J, Murillo O. Shorter treatments for vertebral osteomyelitis. Lancet. 2015;385(9971):836–7.CrossRef
24.
Zurück zum Zitat Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, Le Moal G, Godet C, Mulleman D, Azais I, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum. 2007;36(5):269–77.CrossRef Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, Le Moal G, Godet C, Mulleman D, Azais I, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum. 2007;36(5):269–77.CrossRef
25.
Zurück zum Zitat Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P. Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine. 2007;74(2):133–9.CrossRef Grados F, Lescure FX, Senneville E, Flipo RM, Schmit JL, Fardellone P. Suggestions for managing pyogenic (non-tuberculous) discitis in adults. Joint Bone Spine. 2007;74(2):133–9.CrossRef
26.
Zurück zum Zitat Babouee Flury B, Elzi L, Kolbe M, Frei R, Weisser M, Scharen S, Widmer AF, Battegay M. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis? BMC Infect Dis. 2014;14:226.CrossRef Babouee Flury B, Elzi L, Kolbe M, Frei R, Weisser M, Scharen S, Widmer AF, Battegay M. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis? BMC Infect Dis. 2014;14:226.CrossRef
Metadaten
Titel
Antimicrobial therapy and assessing therapeutic response in culture-negative pyogenic vertebral osteomyelitis: a retrospective comparative study with culture-positive pyogenic vertebral osteomyelitis
verfasst von
Dongwoo Yu
Sang Woo Kim
Ikchan Jeon
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2020
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05669-1

Weitere Artikel der Ausgabe 1/2020

BMC Infectious Diseases 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.